John Byon
Chief Medical Officer Imugene
Dr. Byon has extensive oncology drug development experience in the pharmaceutical and biotechnology industry. At Genentech, he worked on TecentriqÆ (atezolizumab) in hematological malignancies. For over the past 5 years, he has worked in the cell therapy space. First at Juno as the Global Development Lead for orvacabtagene autoleucel (JCARH-125) in Multiple Myeloma. Then at Lyell, working on next generation cell therapy products for solid tumors. Most recently, he was VP, Clinical Development Hematology at Fate Therapeutics, where he oversaw a portfolio of 5 iPSC-derived cell therapies (CAR-NK and CAR-T) in a various hematologic malignancies (AML, MM, B-cell Lymphoma).
Seminars
Tuesday 15th September 2026
Enhancing CAR-T Persistence & Outcomes through IL-2–Driven Optimization & Strategic Combination Therapy
9:30 am
- Demonstrating how low-dose IL-2 postinfusion improves CAR-T pharmacokinetics, persistence, and clinical durability without additional cell engineering
- Discussing combination-based optimization as a practical pathway to overcoming first-generation allo-CAR-T limitations
- Exploring early clinical direction for integrating BTK inhibition to further enhance efficacy and long-term responses
